First off congrats to anyone who bought is and made some money. I passed on this one as there was to much downside potential if it was not passed.
Revenues from past years are weak with this drug. Stock is overbought and see downside from here. Company they bought the drug from only had approx. $20 million in sales over 2 years and invested over $250 million.
"06/13/09 - ATIN - After drug marketer Cephalon spent $250M marketing the ant-craving medication VIVITROL over two years and only succeeded in driving annual sales to $20M or so, the pioneering drug's developer, Alkermes, in January took complete control over VIVITROL."
Revenues for ALKS since buying the drug.
"Net sales of VIVITROL for the quarter ended June 30, 2010, were $6.2 million, compared to net sales of $4.2 million for the same period in 2009."
Thanks for the post and information. I'm guessing that revenue from this drug for opiod use was zero. I'm also guessing it will be somewhat more than zero in the future due to an overwhelming backing by the panel. All I'm saying is the company is better off today than it was yesterday. Combine this with the upcoming PDUFA for this and Bydureon and I actually see near term upside for the company. I will probably hold through the Oct 12 Vivitrol date, as that approval seems pretty likely, and sell sometime during the runup to the Oct 22 date for Bydureon.